Keele Research Repository

Article

Moss, DM, Curley, P, Kinvig, H, Hoskins, C ORCID: https://orcid.org/0000-0002-7200-0566 and Owen, A (2018) The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery. Expert Review of Gastroenterology and Hepatology, 12 (3). pp. 223-236.

Curley, P, Giardiello, M, Liptrott, NJ, Dickens, D, Moss, DM, Hobson, J, Savage, AC, McDonald, T, Siccardi, M, Rannard, S and Owen, A (2017) In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line. Journal of Interdisciplinary Nanomedicine, 2 (3). pp. 157-169.

de Wolf, E, Abdullah, MI, Jones, SM, Menezes, K, Moss, DM, Drijfhout, FP ORCID: https://orcid.org/0000-0002-3210-8038, Hart, S, Hoskins, C ORCID: https://orcid.org/0000-0002-7200-0566, Stronach, EA and Richardson, A ORCID: https://orcid.org/0000-0003-1825-3375 (2017) Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer. Scientific Reports, 7 (1).

Moss, DM, Domanico, P, Watkinson, M ORCID: https://orcid.org/0000-0003-1877-5667, Seonghee, P, Randolph, R, Wring, S, Rajoli, RKR, Hobson, J, Rannard, S, Siccardi, M and Owen, A (2017) Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate. Antimicrobial Agents and Chemotherapy, 61 (7).

Curley, P, Rajoli, RK, Moss, DM, Liptrott, NJ, Letendre, S, Owen, A and Siccardi, M (2016) Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation. Antimicrobial Agents and Chemotherapy, 61 (1).

Giardiello, M, Liptrott, NJ, McDonald, T, Moss, DM, Siccardi, M, Martin, P, Smith, D, Gurjar, R, Rannard, S and Owen, A (2016) Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. Nature Communications, 7.

Curley, P, Moss, DM, Siccardi, M and Owen, A (2016) Development and Validation of a LC-MS/MS Assay for the Quantification Of Efavirenz In Different Biological Matrices. Bioanalysis, 8 (20). pp. 2125-2134.

Moss, DM, Marzolini, C, Rajoli, RK and Siccardi, M (2015) Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. Expert Opinion on Drug Metabolism and Toxicology, 11 (8). pp. 1203-1217.

Moss, DM, Liptrott, NJ, Siccardi, M and Owen, A (2015) Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. Frontiers in Pharmacology, 6.

Capper, MJ, O'Neil, PM, Fisher, N, Strange, RW, Moss, DM, Ward, SA, Biagini, GA and Antonyuk, SV (2015) Antimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc1. Proceedings of the National Academy of Sciences, 112 (3). pp. 755-760.

Moss, DM, Neary, M and Owen, A (2014) The role of drug transporters in the kidney: lessons from tenofovir. Frontiers in Pharmacology, 5.

Moss, DM and Siccardi, M (2014) Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling. British Journal of Pharmacology, 171 (17). pp. 3963-3979.

Moss, DM, Curley, P, Shone, A, Siccardi, M and Owen, A (2014) A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. Journal of Antimicrobial Chemotherapy, 69 (12). pp. 3275-3281.

Moss, DM, Liptrott, NJ, Curley, P, Siccardi, M, Back, DJ and Owen, A (2013) Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro. Antimicrobial Agents and Chemotherapy, 57 (11). pp. 5612-5618.

Moss, DM, Siccardi, M, Back, DJ and Owen, A (2013) Predicting intestinal absorption of raltegravir using a population-based ADME simulation. Journal of Antimicrobial Chemotherapy, 68 (7). pp. 1627-1634.

Nixon, G, Moss, DM, Shone, A, Lalloo, D, Fisher, N, O'Neill, P, Ward, S and Biagini, G (2013) Antimalarial pharmacology and therapeutics of atovaquone. Journal of Antimicrobial Chemotherapy, 68 (5). pp. 977-985.

Moss, DM, Siccardi, M, Murphy, M, Piperakis, MM, Khoo, SH, Back, DJ and Owen, A (2012) Divalent metals and pH alter raltegravir disposition in vitro. Antimicrobial Agents and Chemotherapy, 56 (6). pp. 3020-3026.

Moss, DM, Kwan, WS, Liptrott, NJ, Smith, DL, Siccardi, M, Khoo, SH, Back, DJ and Owen, A (2011) Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir. Antimicrobial Agents and Chemotherapy, 55 (2). pp. 879-887.